11/24
07:00 am
tnxp
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Medium
Report
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
11/17
07:22 am
tnxp
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment [Yahoo! Finance]
11/17
07:00 am
tnxp
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
Medium
Report
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
11/14
09:42 am
tnxp
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook [Seeking Alpha]
Low
Report
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook [Seeking Alpha]
11/12
05:43 am
tnxp
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News [Yahoo! Finance]
Low
Report
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News [Yahoo! Finance]
11/10
04:32 pm
tnxp
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
11/10
04:15 pm
tnxp
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Low
Report
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
11/6
07:00 am
tnxp
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
Medium
Report
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
11/4
07:00 am
tnxp
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
Medium
Report
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
10/28
07:00 am
tnxp
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
Medium
Report
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
10/27
07:00 am
tnxp
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
Medium
Report
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
10/22
07:00 am
tnxp
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Low
Report
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
10/21
07:00 am
tnxp
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Low
Report
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
10/17
07:00 am
tnxp
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
Low
Report
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
10/14
07:07 am
tnxp
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation [Yahoo! Finance]
10/14
07:00 am
tnxp
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
Low
Report
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
10/9
08:01 am
tnxp
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 [Yahoo! Finance]
10/9
07:00 am
tnxp
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
Low
Report
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
10/4
12:06 am
tnxp
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
Low
Report
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
9/30
08:30 am
tnxp
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
Medium
Report
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
9/29
07:16 am
tnxp
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 [Yahoo! Finance]
9/29
07:00 am
tnxp
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Medium
Report
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
9/18
08:00 am
tnxp
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
Low
Report
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
9/17
07:00 am
tnxp
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Low
Report
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
9/8
07:00 am
tnxp
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
Medium
Report
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025